Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.036 USD -12.2%
Market Cap: $9.5m
Write Note Create Alert Ask AI

Bankruptcy Probability

Adaptimmune Therapeutics PLC's probability of bankruptcy is hidden . The solvency score is hidden .

We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.

Bankruptcy Probability
HIDDEN
Show

Financial Position

Cash & ST Investments
+
3Y
-90%
5Y
-94%
10Y
-
Long-Term Investments
+
3Y
-
5Y
-
10Y
-
Debt
+
3Y
-
5Y
-
10Y
-

Solvency Ratios

Solvency Ratios Comparison
Adaptimmune Therapeutics PLC Competitors

Country Company Market Cap D/E D/A Interest
Coverage 		Altman
Z-Score 		Quick
Ratio 		Current
Ratio 		Cash
Ratio
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
9.5m USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Abbvie Inc
NYSE:ABBV
383.2B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
201.5B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
181.6B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.9B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
87.9B AUD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
43.9B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
No Stocks Found

See Also

Summary
ADAP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADAP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADAP stock valuation using valuation multiples.
Wall Street Estimates
ADAP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADAP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Is Adaptimmune Therapeutics PLC at risk of bankruptcy?

Adaptimmune Therapeutics PLC's probability of bankruptcy is hidden .

The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.

How much debt does Adaptimmune Therapeutics PLC have?

As of the latest report, Adaptimmune Therapeutics PLC has total debt of 25.7m USD. This includes both short-term (0 USD) and long-term (25.7m USD) debt.

You can find a full breakdown on its Balance Sheet.

Back to Top
ALPHA SPREAD
Follow us
Join more than 315,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.